NABI GETS ORPHAN DRUG LABEL IN EUROPE

Nabi Biopharmaceuticals said Wednesday that European regulators designated its experimental liver disease treatment an "orphan medicinal product" - a label that means the drug could qualify for 10 years of exclusive selling rights in the region. The designation also reduces the company's application fees, gives it free access to certain scientific advisers and provides other benefits for research and development. Nabi's Civacir drug is designed to prevent recurrent, hepatitis-C induced liver disease in transplant patients.

Forbes (http://www.forbes.com/technology/ebusiness/feeds/ap/2005/06/22/ap2107177.html)